History
  • No items yet
midpage
65 F.Supp.3d 283
D. Mass.
2014
Read the full case

Background

  • Forest Laboratories marketed Celexa and Lexapro (SSRIs) and sought pediatric MDD indications; FDA typically requires two positive placebo-controlled trials for approval.
  • Clinical trials: one Celexa study (MD-18) and one Lexapro study (Study 32) were positive; the Lundbeck Celexa study and Lexapro Study 15 were negative. FDA denied a pediatric Celexa indication in 2002; in 2005 labels were revised to disclose negative pediatric data; Lexapro received an adolescent indication in 2009 based on combined data.
  • The DOJ unsealed a qui tam complaint in 2009 alleging off-label pediatric promotion and concealment of the Lundbeck Study; multiple putative class actions followed, including a March 2009 national RICO suit and the Jaeckel consumer class action.
  • Two TPP plaintiffs sued Forest in the MDL: Painters (filed 2013 FAC asserting RICO and Minnesota consumer claims) and Allied Services/NM UFCW (filed 2014 asserting RICO, state consumer statutes, and unjust enrichment).
  • Forest moved to dismiss both complaints for, inter alia, statute-of-limitations defects and failure to plead RICO and state-law elements; the court held hearings and resolved the motions by opinion dated December 12, 2014.

Issues

Issue Plaintiff's Argument Defendant's Argument Held
Accrual and SOL for RICO Injury is payment caused by fraud; discovery in 2013; timely. Injury was payment for ineffective drugs and was discoverable by 2005 (label changes, press). SOL did not accrue later than March 2009 (when national RICO suit was filed); Painters’ RICO claims saved by tolling from the March 2009 RICO filing.
American Pipe tolling for non-identical claims Earlier class filings (Jaeckel and others) tolled SOL for subsequent RICO claims. Tolling applies only where earlier complaint asserted identical claims. Jaeckel (consumer suit) did not toll RICO claims; March 2009 RICO complaint did toll Painters’ RICO claims despite later voluntary dismissal.
Sufficiency of RICO pleading (standing, enterprise, predicates) Alleged payments for ineffective drugs, enterprise of Forest/subsidiaries/academics, predicate mail/wire fraud tied to off-label promotion. Lack of injury proof, no common purpose among alleged associates, predicates not pleaded with Rule 9(b) particularity. FAC adequately pleaded injury/standing, an association-in-fact (for now), and predicate mail/wire fraud (incorporating plea/information), so RICO claims survive dismissal.
State consumer-law and unjust enrichment claims (Painters and Allied Services/NM UFCW) Plaintiffs allege deceptive promotion caused payments; seek damages. Many state claims are time-barred or improperly pleaded; some remedies limited (e.g., MDTPA injunctive relief only). Painters’ Minnesota claims (MCFA, MUTPA) survive for payments within six-year window; MDTPA count dismissed (statute allows injunctive relief only). Allied Services/NM UFCW state claims dismissed as time-barred or otherwise deficient; extra-state consumer claims dismissed.

Key Cases Cited

  • Bell Atl. Corp. v. Twombly, 550 U.S. 544 (standards for plausibility on a motion to dismiss)
  • Ashcroft v. Iqbal, 556 U.S. 662 (pleading standards; courts need not accept legal conclusions)
  • Rotella v. Wood, 528 U.S. 549 (RICO accrual: discovery of injury starts SOL)
  • Sedima, S.P.R.L. v. Imrex Co., 473 U.S. 479 (elements of a §1962(c) RICO claim)
  • Boyle v. United States, 556 U.S. 938 (definition and requirements for association-in-fact enterprise)
  • H.J., Inc. v. Northwestern Bell Tel. Co., 492 U.S. 229 (pattern of racketeering requirement)
  • American Pipe & Constr. Co. v. Utah, 414 U.S. 538 (class-action filing tolls SOL for putative class members)
  • Crown, Cork & Seal Co. v. Parker, 462 U.S. 345 (American Pipe tolling extends to putative class members)
  • In re Lupron Mktg. & Sales Practices Litig., 295 F. Supp. 2d 148 (statute-of-limitations typically a jury question)
  • In re Neurontin Mktg. & Sales Practices Litig., 712 F.3d 21 (First Circuit discussion of American Pipe tolling and related pleading issues)
Read the full case

Case Details

Case Name: In Re: Celexa and Lexapro Marketing and Sales Practices Litigation
Court Name: District Court, D. Massachusetts
Date Published: Dec 12, 2014
Citations: 65 F.Supp.3d 283; 1:09-md-02067
Docket Number: 1:09-md-02067
Court Abbreviation: D. Mass.
Log In
    In Re: Celexa and Lexapro Marketing and Sales Practices Litigation, 65 F.Supp.3d 283